|
|
Cat. No |
Model |
Description |
Unit |
Price (VATº°µµ) |
³³±â |
Àç°í |
DataSheet |
ÁÖ¹®/°ßÀû |
LCA-23-310925 |
NB110-57475 |
alpha Synuclein Antibody (EP1646Y)//Human, Mouse,/Rabbit |
1/EA |
|
|
|
|
¹®ÀÇ |
|
|
|
|
|
|
Subject
|
alpha Synuclein Antibody (EP1646Y) |
Description
|
/ Human, Mouse,/Rabbit |
Clonality
|
Mono |
Company
|
Novus biologicals |
Application
|
ICC, Western Blot |
Conjugation
|
|
Immunogen
|
|
Contents
|
Description:Summary: Species: | Rt, Mu, Hu | Applications: | ICC, WB | Clonality: | Monoclonal | | Gene: | SNCA | Purity: | IgG purified | Host: | Rabbit | | Specificity: | A synthetic peptide corresponding to residues on the N-terminus of human Alpha-synuclein was used as an immunogen. | Publications: | Antibody has not yet been mentioned in a publication. | Details: Clone: | EP1646Y | Isotype: | IgG | Immunogen: | A synthetic peptide contained within amino acid residues 1-50. | Gene Symbol: SNCA Entrez: | 6622 (Human) | | 20617 (Mouse) | | 29219 (Rat) | Swiss Prot: | P37840 (Human) | Related Genes: | PARK2, MAPT, SNCB, PARK7, SNCAIP, TH, APP, LRRK2, UCHL1, PINK1, PRNP, NLRP1, UCHL3, HTT, TPO, SYP, CASP3, SLC6A3, HSPA4, SCG2, SIGLEC1, PSEN1, SOD1, YWHAQ, APOE, MAPK1, TPPP, TG, CYCS, FAM49B, TNF, CHM, MAPK8, MPZ, MPHOSPH6, ATP13A2, BDNF, AKT1, NR4A2, SNCG | Background: Alpha-synuclein is expressed predominantly in brain, where it is concentrated in presynaptic nerve terminals (1). The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Phosphorylation of alpha-synuclein at Ser 129 promoted fibril formation in vitro and these results highlight the importance of phosphorylation of filamentous proteins in the pathogenesis of neurodegenerative disorders (2). Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin. It is hypothesized that parkin and alpha-synculein interact functionally, namely, that parkin ubiquitinates alpha-synuclein normally and that this process is altered in autosomal recessive PD (3). Species: Reactivity: | Cross reacts in Human, Mouse and Rat. | Applications: Uses: | Western Blot and Immunocytochemistry | Dilutions: | Western Blot 1:50000, Immunocytochemistry 1:50 - 100 | Positive Controls: | 1 positive controls | Packaging: Buffer: | 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, and 0.05% BSA. | Storage: | Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles. | Preservative: | 0.01% Sodium Azide | Limitations: | This product is for research use only and is not approved for use in humans or in clinical diagnosis. Products are guaranteed for 6 months from date of receipt, except for peptides and proteins which are guaranteed for 3 months. | | | |
|
|
|
|